1. Home
  2. POAS vs ONCO Comparison

POAS vs ONCO Comparison

Compare POAS & ONCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Phaos Technology Holdings (Cayman) Limited Class A Ordinary Shares

POAS

Phaos Technology Holdings (Cayman) Limited Class A Ordinary Shares

SELL

Current Price

$2.65

Market Cap

2.8M

Sector

Industrials

ML Signal

SELL

Logo Onconetix Inc.

ONCO

Onconetix Inc.

HOLD

Current Price

$0.48

Market Cap

3.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
POAS
ONCO
Founded
2017
2018
Country
Singapore
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.8M
3.0M
IPO Year
2024
2021

Fundamental Metrics

Financial Performance
Metric
POAS
ONCO
Price
$2.65
$0.48
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
161.6K
★ 6.4M
Earning Date
11-21-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 22.80
EPS
★ N/A
N/A
Revenue
N/A
★ $815,371.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.13
$0.09
52 Week High
$7.40
$798.00

Technical Indicators

Market Signals
Indicator
POAS
ONCO
Relative Strength Index (RSI) 88.31 34.16
Support Level $1.51 $0.09
Resistance Level $2.83 $1.02
Average True Range (ATR) 0.22 0.09
MACD 0.27 -0.02
Stochastic Oscillator 82.44 1.86

Price Performance

Historical Comparison
POAS
ONCO

About POAS Phaos Technology Holdings (Cayman) Limited Class A Ordinary Shares

Phaos Technology Holdings Cayman Ltd is an investment holding company incorporated in the Cayman Islands. Through its subsidiaries, the Company engages in the research, development, manufacturing, and commercialization of optical technologies and products. Leveraging its patented microsphere technology, Phaos enhances the magnification of traditional optical microscopes, enabling visualization beyond the 200nm optical limit at a commercially viable working distance. The Company offers high tech microscopy equipment and parts, along with AI-powered software solutions that complement its hardware to deliver fully integrated microscopy systems. Its technologies serve diverse sectors, including manufacturing, biomedical, and research.

About ONCO Onconetix Inc.

Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. The company owns Proclarix, an in vitro diagnostic test for prostate cancer, approved for sale in the European Union. Additionally, it is focused on marketing Proclarix in the U.S. as a lab-developed product. Onconetix operates in one segment: commercial. Geographically, the company generates maximum revenue from Switzerland and the rest from the United Kingdom.

Share on Social Networks: